pyrrolidine dithiocarbamate has been researched along with sulindac in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jakubowska-Mućka, A; Lasek, W; Sieńko, J; Wolny, R; Zapała, Ł | 1 |
| Chen, HX; Hu, LN; Li, JK; Peng, X; Xie, LX | 1 |
2 other study(ies) available for pyrrolidine dithiocarbamate and sulindac
| Article | Year |
|---|---|
Synergistic cytotoxic effect of sulindac and pyrrolidine dithiocarbamate against ovarian cancer cells.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Female; Flow Cytometry; Humans; NF-kappa B; Ovarian Neoplasms; Prostaglandin-Endoperoxide Synthases; Pyrrolidines; Resting Phase, Cell Cycle; Sulindac; Thiocarbamates; Time Factors | 2012 |
[Effects of NF-kappaB inhibitor on cisplatin-induced apoptosis in cervical cancer].
Topics: Apoptosis; Aspirin; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Curcumin; Female; Humans; NF-kappa B; Pyrrolidines; Sulindac; Thiocarbamates; Uterine Cervical Neoplasms | 2013 |